RxDoctor Payments Data

Vlascovia Velasco Rios, PA

Physician Assistant · Ceres, CANPI 1396923454

Payments from drug & device makers

$3,050in general payments, 2019–2025

Across 227 payments — averaging $13.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$477
  • Lilly USA, LLC$463
  • Novo Nordisk$394
  • Biohaven Pharmaceutical Holding Company Ltd.$168
  • Exact Sciences$123
  • Pfizer$113
  • plus $1K from 32 others

What the payments were for

  • Food & beverage$3,050100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,050 in reported general payments places this provider in the 85th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$31,742
Medicare patients
105
Services billed
442

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin158$175,888
OzempicSemaglutide59$57,033
FarxigaDapagliflozin Propanediol70$52,945
RybelsusSemaglutide42$52,581
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$39,020
EliquisApixaban51$38,250
JanuviaSitagliptin Phosphate38$31,919
MounjaroTirzepatide26$31,031
JanumetSitagliptin Phos/Metformin Hcl29$25,941
TrulicityDulaglutide25$22,735
Diflorasone Diacetate14$10,309
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$9,226
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$7,331
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,184
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr16$6,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$99$183,219172 claims
Novo NordiskOzempic, Rybelsus$394$109,614101 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$44$63,26792 claims
MerckJanuvia, Janumet$36$57,86067 claims
Lilly USA, LLCMounjaro, Trulicity$463$53,76551 claims
GSKTrelegy Ellipta, Anoro Ellipta$31$45,49277 claims
PfizerEliquis$113$38,25051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Ceres

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →